Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Neuroectodermal Tumors × Lomustine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 19 Brain Neoplasms 15 Central Nervous System Neoplasms 14 Astrocytoma 9 Glioma 7 Oligodendroglioma 5 Medulloblastoma 4 Neoplasms 3 Lymphoma 3 Gliosarcoma 3 Recurrence 2 Melanoma 2 Lymphoma, AIDS-Related 2 Leukemia, Myeloid, Acute 2 Uveal Melanoma 1 Spinal Cord Neoplasms 1 Solid Tumor 1 Optic Nerve Glioma 1 Neuroectodermal Tumors 1 Lung Neoplasms 1 Intraocular Lymphoma 1 Familial ependymoma 1 Ependymoma 1 Drug-Related Side Effects and Adverse Reactions 1 Cognition Disorders 1 Carcinoma, Non-Small-Cell Lung 1 Camurati-Engelmann Syndrome 1 Adenocarcinoma, Bronchiolo-Alveolar 1 Adenocarcinoma of Lung 1

Interventions

pralsetinib 1 pembrolizumab 1 pamiparib 1 cixutumumab 1 Vincristine 1 Valproic Acid 1 Radiotherapy 1 Radiation 1 Oncolytic Virotherapy 1 Maintenance Chemotherapy 1 Lomustine 1 Etoposide 1 Cisplatin 1 Antibodies, Monoclonal 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01614132 2020-03-31

NOA-07

University of Regensburg

Phase 1/2 Completed

Medulloblastoma, Neoplasms, Neuroectodermal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡